Last updated: August 13, 2026
White petrolatum is a mature, specification-driven pharmaceutical excipient used mainly in topical ointments, creams, barrier products, ophthalmic preparations, and dermatological formulations. Its market is stable rather than high-growth. Volume demand tracks generic topical drugs, prescription dermatology, over-the-counter skin protectants, wound care, and personal-care products.
Standalone global revenue for pharmaceutical-grade white petrolatum is not publicly disclosed by major suppliers. Public company filings generally report broader specialty ingredients, petroleum products, or personal-care businesses. Financial analysis therefore depends on end-market indicators, refinery feedstock economics, pricing, capacity, regulatory qualification, and supplier concentration rather than a transparent market-size series.
What is white petrolatum and how is it used as a pharmaceutical excipient?
White petrolatum is a purified, semi-solid mixture of saturated hydrocarbons derived from petroleum. It is also called white soft paraffin or petrolatum, depending on the applicable pharmacopeial standard and market.
| Attribute |
Pharmaceutical relevance |
| Chemical identity |
Complex mixture of highly refined hydrocarbons |
| CAS number |
8009-03-8 |
| Primary function |
Ointment base, occlusive agent, emollient, skin protectant |
| Common dosage forms |
Ointments, creams, balms, gels, ophthalmic products |
| Main routes |
Topical, dermal, ophthalmic |
| Key quality attributes |
Purity, color, odor, consistency, melting range, hydrocarbon profile |
| Principal standards |
USP-NF, Ph. Eur., BP and national standards |
| FDA status |
Recognized active ingredient for certain OTC skin-protectant products; widely listed as an inactive ingredient |
White petrolatum is valued for its low reactivity, water-barrier properties, long shelf life, low microbiological risk when properly manufactured, and compatibility with many active pharmaceutical ingredients. Its disadvantages include a greasy sensory profile, limited water absorption, poor washability, and dependence on petroleum-derived feedstocks.
The FDA OTC skin-protectant monograph permits petrolatum at concentrations ranging from 30% to 100% for specified skin-protectant claims, subject to applicable labeling and formulation conditions [1]. In many prescription products, white petrolatum is an excipient rather than the pharmacologically active ingredient.
What is the pharmaceutical-grade white petrolatum market size?
A precise standalone market size cannot be established from public filings because suppliers do not separately report pharmaceutical white petrolatum revenue. Commercial market reports often combine petrolatum with petroleum jelly, mineral oils, paraffin waxes, ointment bases, or broader cosmetic ingredients. Those aggregated estimates should not be treated as direct measures of the pharmaceutical excipient segment.
The pharmaceutical segment is smaller than the personal-care and industrial segments but has higher qualification requirements and generally better pricing. Demand is linked to:
- Generic dermatology products.
- Prescription wound-care and burn products.
- OTC skin protectants.
- Pediatric and barrier creams.
- Ophthalmic ointments.
- Veterinary topical products.
- Contract-manufactured creams and ointments.
The market is best characterized as mature, recurring, and moderately fragmented by region. Volume growth is likely low single digit in established markets, with higher growth in developing markets where branded and generic topical medicines are expanding. Price growth can exceed volume growth during periods of feedstock inflation, energy-cost increases, freight disruption, or supply qualification constraints.
Which companies manufacture pharmaceutical-grade white petrolatum?
The principal competitive set includes petroleum refiners, specialty hydrocarbon processors, and pharmaceutical excipient suppliers. Product availability varies by grade, region, compendial certification, packaging, and regulatory documentation.
| Supplier or supplier group |
Relevant market position |
| Sonneborn |
Major supplier of specialty hydrocarbons, including pharmaceutical and personal-care petrolatum grades |
| Calumet Specialty Products Partners |
Produces specialty hydrocarbon products, including petrolatum and related personal-care materials |
| Sasol |
Supplies specialty waxes, emollients and hydrocarbon ingredients in multiple markets |
| Nynas |
Specialty naphthenic and bitumen-related producer with adjacent technical capabilities, though product fit varies by grade |
| Penreco and related specialty hydrocarbon businesses |
Supplies petroleum-derived specialty ingredients and gelled hydrocarbon systems |
| Regional refiners and excipient distributors |
Provide qualified or repackaged grades, often with narrower geographic coverage |
Manufacturing capacity is not equivalent to pharmaceutical qualification. A producer may make technical or cosmetic petrolatum without holding the documentation, validation package, change-control history, audit record, and compendial conformity required by a pharmaceutical customer.
How does the white petrolatum supply chain affect pricing?
White petrolatum pricing is driven primarily by petroleum feedstocks and refining economics. The principal cost variables are:
- Crude oil and refinery feedstock prices.
- Hydrogenation and purification costs.
- Energy consumption.
- Specialty processing capacity.
- Packaging and freight.
- Regulatory testing and quality assurance.
- Customer qualification and inventory requirements.
The product is less exposed to crude-oil price changes than unrefined petroleum products because pharmaceutical-grade material requires additional processing. Its pricing also reflects the cost of maintaining dedicated quality systems and producing consistent batches.
The most important commercial distinction is between bulk technical petrolatum and qualified pharmaceutical-grade white petrolatum. Pharmaceutical buyers usually pay for documented consistency, not merely hydrocarbon content. A low-cost technical substitute may fail color, polycyclic aromatic hydrocarbon, impurity, microbiological, or compendial requirements.
What creates supply-chain risk?
Supply risk is concentrated in qualified production rather than in the existence of petroleum feedstock. The main risks are:
- Refinery closures that reduce specialty feedstock availability.
- Discontinuation of low-volume pharmaceutical grades.
- Supplier changes in refining, hydrogenation, packaging, or site location.
- Transport restrictions involving petroleum-derived materials.
- Regional shortages of approved packaging.
- Long customer requalification timelines.
- Divergence between USP-NF and European or national pharmacopeial requirements.
Pharmaceutical manufacturers typically manage this risk through dual sourcing, safety stock, supplier audits, and formal change-control agreements. A second supplier is not immediately interchangeable if its grade has not been incorporated into the finished-product regulatory file.
What FDA regulatory status applies to white petrolatum?
White petrolatum has two distinct regulatory roles.
Active ingredient in OTC skin protectants
Under the FDA skin-protectant framework, petrolatum is an accepted active ingredient for specified claims, including temporary protection of minor cuts, scrapes, burns, and chapped or cracked skin, when used within the applicable monograph conditions [1].
This status can reduce the need for a product-specific new drug application when the finished product complies with the monograph. It does not remove obligations relating to manufacturing, labeling, stability, adverse-event reporting, and quality.
Inactive pharmaceutical ingredient
White petrolatum is also used as an excipient in prescription and nonprescription products. The FDA Inactive Ingredient Database records excipient use by dosage form and route. Database presence supports precedent but does not automatically establish approval for every concentration, route, or product type [2].
For a new formulation, regulatory review can focus on:
- Identity and grade.
- Compendial compliance.
- Impurity profile.
- Microbial quality.
- Container compatibility.
- Stability and oxidation behavior.
- Route-specific safety.
- Supplier and manufacturing-site controls.
What patents protect white petrolatum formulations?
The base substance is a mature petroleum-derived material. Broad composition patents are unlikely to provide meaningful exclusion around ordinary white petrolatum itself. Commercial protection usually arises from formulation-specific patents, process know-how, trade secrets, and regulatory data rather than ownership of the excipient.
Potentially relevant patent categories include:
- Topical formulations containing petrolatum and an active drug.
- Barrier creams combining petrolatum with ceramides, zinc oxide, silicones, or botanical ingredients.
- Ophthalmic ointments using petrolatum and mineral oil systems.
- Controlled-release or enhanced-penetration formulations.
- Wound-care compositions containing petrolatum and antimicrobial agents.
- Manufacturing and purification processes.
- Packaging systems that improve stability or dosing.
Patent expiry must be assessed at the finished-product level. A patent covering a dermatology formulation does not prevent use of white petrolatum in unrelated products. Conversely, a formulation patent can delay generic entry even when the excipient itself is unpatented.
What is the Orange Book status of white petrolatum?
White petrolatum is not ordinarily listed in the Orange Book as an independently patented active pharmaceutical product. The Orange Book concerns approved drug products and related patent and exclusivity information, not a general patent registry for excipients [3].
A white-petrolatum-containing product may have Orange Book-listed patents if the finished product is an approved drug with listed patents covering its active ingredient, formulation, method of treatment, or other qualifying claims. The relevant analysis is product-specific.
A generic applicant could face:
- Paragraph IV certification against a listed patent.
- A 30-month stay if the patent holder files timely litigation.
- Non-patent regulatory exclusivity.
- Formulation or method-of-use patents.
- Commercial barriers caused by supplier qualification rather than patent law.
When does white petrolatum lose exclusivity?
White petrolatum has no single market-wide exclusivity date. It is a mature excipient with no central composition exclusivity comparable to a new chemical entity.
Exclusivity can still apply to particular finished products through:
- New-drug exclusivity.
- Pediatric exclusivity.
- Orphan-drug exclusivity.
- Formulation patents.
- Method-of-use patents.
- Device or packaging patents.
- Regulatory protection for specific products.
For ordinary generic topical products, the principal barriers are usually formulation development, bioequivalence or therapeutic-equivalence requirements, manufacturing scale-up, and customer or regulatory qualification. Paragraph IV litigation is relevant only when the target finished product has listed patents.
How strong is the patent estate for white petrolatum?
The direct patent estate for the excipient is weak because the material is longstanding and broadly used. The commercial moat is stronger at the supplier and product-quality level.
| Protection type |
Strength for ordinary white petrolatum |
| Broad composition patent |
Low |
| Manufacturing know-how |
Moderate |
| Supplier quality system |
Moderate to strong |
| Site and process qualification |
Strong for incumbent supply relationships |
| Formulation patents |
Variable and product-specific |
| Trade secrets |
Moderate |
| Regulatory precedent |
Moderate |
| Switching costs |
Moderate to strong |
The most durable advantage is customer qualification. Pharmaceutical companies may avoid switching suppliers because a change can trigger comparability work, stability studies, process validation, regulatory notification, and commercial risk. This creates retention even when the underlying substance is not patent-protected.
What generic entry risks exist for products containing white petrolatum?
Generic entry risk is generally high for simple topical products with established formulations and no enforceable formulation patents. It is lower when products have:
- Complex emulsions or multiphase systems.
- Proprietary particle size or rheology.
- Difficult-to-characterize local delivery.
- Device-dependent administration.
- Combination claims.
- Clinical or comparative-performance requirements.
- Multiple active patents.
- Limited availability of qualified excipient suppliers.
White petrolatum itself does not usually create a generic barrier. It can create development risk when the reference product uses a specific grade, mixture, consistency, or processing history that materially affects spreadability, drug release, water loss, or skin feel.
How does white petrolatum compare with alternative ointment bases?
| Excipient or base |
Relative advantage |
Relative limitation |
| White petrolatum |
Strong occlusion, low reactivity, low cost, long shelf life |
Greasy, difficult to wash off, limited water absorption |
| Mineral oil |
Improves spreadability and softness |
Less structured and less occlusive alone |
| Paraffin wax |
Increases structure and melting point |
Can reduce spreadability |
| Lanolin |
Emollient and water-absorbing |
Higher sensitization concern |
| Polyethylene glycol bases |
Water-soluble and washable |
Can sting or irritate; different drug-release behavior |
| Silicone bases |
Good sensory profile and water resistance |
Higher cost; formulation-specific compatibility |
| Plant-derived oils and butters |
Consumer acceptance and emollience |
Oxidation, variability, and allergen concerns |
White petrolatum remains difficult to displace in low-cost occlusive ointments. Substitution is more likely in premium skin care, cosmetically sensitive products, and formulations requiring washability or controlled sensory performance.
What is the financial trajectory for white petrolatum suppliers?
The financial trajectory is likely to show stable base demand with cyclical pricing. Revenue growth can come from price increases, geographic expansion, premium pharmaceutical grades, and higher-value blends rather than rapid unit-volume expansion.
| Financial driver |
Expected effect |
| Crude and feedstock inflation |
Raises selling prices and working capital |
| Refinery rationalization |
Can tighten supply and support margins |
| Generic topical growth |
Supports recurring volume |
| OTC skin-protectant demand |
Provides defensive demand |
| Premium compendial grades |
Supports higher realized pricing |
| Personal-care substitution |
Limits long-term volume growth |
| Freight and packaging costs |
Compresses margins when contracts lag costs |
| Dual sourcing by customers |
Limits supplier pricing power |
| Qualification barriers |
Improves retention and contract stability |
The strongest earnings profile is likely to occur in suppliers that combine white petrolatum with mineral oils, waxes, esters, silicones, and formulation services. A company dependent on a single petroleum-derived ingredient has greater exposure to commodity volatility and refinery disruptions.
Public financial statements should be interpreted carefully. Calumet’s disclosures, for example, report broad specialty-products performance rather than a separately audited white-petrolatum business. Similar limitations apply to diversified ingredient suppliers. Product-level market-share and margin claims require proprietary company data or paid industry research [4].
Which geographic markets offer the strongest growth?
North America and Western Europe are mature, regulated markets with stable pharmaceutical demand and high qualification standards. Growth is more likely to come from product mix and pricing than from large volume increases.
Asia-Pacific offers stronger volume potential because of:
- Expanding generic-drug manufacturing.
- Rising dermatology and wound-care consumption.
- Growth in contract manufacturing.
- Increased use of standardized excipients.
- Development of local pharmaceutical production.
India and China are important manufacturing and consumption markets, but local suppliers may compete aggressively on price. International suppliers retain an advantage where multinational customers require globally consistent documentation, auditability, and change control.
Latin America, the Middle East, and Africa have demand growth potential but face greater exposure to import logistics, currency volatility, registration delays, and distributor concentration.
What manufacturing and intellectual-property barriers affect market entry?
The technical barrier to making ordinary petrolatum is lower than the barrier to supplying pharmaceutical-grade white petrolatum at scale. A new entrant must establish:
- Consistent feedstock sourcing.
- Purification and hydrogenation controls.
- Validated processing.
- Compendial testing.
- Impurity and hydrocarbon profiling.
- Stability data.
- GMP-compliant quality systems.
- Audit readiness.
- Packaging and shipping controls.
- Change-notification procedures.
The principal barrier is commercial qualification. Pharmaceutical customers often require multiple batches, stability support, supplier audits, quality agreements, and regulatory documentation before approving a new source. This process can take materially longer than ordinary industrial customer qualification.
What litigation and settlement issues affect white petrolatum?
There is no general white-petrolatum patent litigation framework comparable to a branded small-molecule drug. Disputes are more likely to involve:
- Finished-product formulation patents.
- Trade-secret claims.
- Supplier contract breaches.
- Product-quality deviations.
- Contamination or adulteration.
- Mislabeling of pharmaceutical versus cosmetic grade.
- Patent infringement involving a drug product that uses petrolatum as an excipient.
Settlement agreements in generic litigation generally concern the finished drug product, not the underlying white petrolatum supply. A supplier may be commercially important without being a party to the relevant patent dispute.
Key Takeaways
- White petrolatum is a mature pharmaceutical excipient with stable recurring demand.
- Standalone global revenue is not publicly disclosed by major suppliers.
- Pharmaceutical-grade pricing exceeds technical-grade pricing because of qualification, testing, documentation, and consistency requirements.
- Demand is supported by generic dermatology, OTC skin protectants, wound care, ophthalmic ointments, and contract manufacturing.
- Feedstock, refinery capacity, energy, freight, and supplier qualification drive financial performance.
- Broad composition patent protection is weak or generally immaterial for ordinary white petrolatum.
- Formulation and method-of-use patents can remain important for finished drug products.
- Generic entry risk is high for simple petrolatum-based products and lower for complex formulations.
- The strongest supplier economics come from broader specialty portfolios rather than white petrolatum alone.
- Asia-Pacific offers the clearest volume-growth opportunity, while North America and Europe provide higher regulatory and qualification value.
FAQs
Is white petrolatum the same as petroleum jelly?
White petrolatum is the highly purified pharmaceutical or cosmetic form of petroleum jelly. Commercial petroleum jelly may refer to products with different purity, color, odor, or regulatory specifications.
Can white petrolatum be used in ophthalmic products?
Yes. Pharmaceutical-grade petrolatum is used in ophthalmic ointments, but the finished product must meet applicable sterility, particulate, compatibility, and route-specific requirements.
Is white petrolatum biodegradable?
White petrolatum is petroleum-derived and is not generally treated as a rapidly biodegradable excipient. Environmental treatment depends on the specific composition, release pathway, and applicable jurisdiction.
Does white petrolatum cause drug-release problems?
It can. Its hydrophobic and occlusive properties may alter active-ingredient solubility, diffusion, release rate, and skin penetration. Each formulation requires product-specific development and stability evaluation.
Can a manufacturer switch from one white-petrolatum supplier to another without regulatory work?
Usually not without assessment. The extent of work depends on the finished product, regulatory filing, grade equivalence, manufacturing impact, stability data, and applicable change-control requirements.
References
-
U.S. Food and Drug Administration. (2024). 21 C.F.R. Part 347: Skin protectant drug products for over-the-counter human use. Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-347
-
U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
Calumet Specialty Products Partners, L.P. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission. https://www.sec.gov/ixviewer/doc/action?doc=("")]
// иҟаз 恒一
